Bernhard Witzenbichler

TL;DR: It is suggested that EC progenitors may be useful for augmenting collateral vessel growth to ischemic tissues (therapeutic angiogenesis) and for delivering anti- or pro-angiogenic agents, respectively, to sites of pathologic or utilitarianAngiogenesis.

TL;DR: Sequential characterization of the in vivo, histological, and molecular findings in this novel animal model document the role of VEGF as endogenous regulator of angiogenesis in the setting of tissue ischemia and represent a potential means for studying the effects of gene targeting on nutrient angiogenic in vivo.

TL;DR: The demonstration that Tie2 as well as angiopoietin-1 are expressed in normal human arteries and veins suggests that the role of angioietin/Tie2 may extend beyond embryonic angiogenesis to maintaining integrity of the adult vasculature.

TL;DR: The pleiotropic effects of certain growth factors may potentiate angiogenesis via a combination of direct effects on EC proliferation and migration and indirect effects that result in the generation of other potent EC mitogens from non-EC populations.

TL;DR: In contrast to the results of gene targeting experiments, constitutive expression of V EGF-C in adult animals promotes angiogenesis in the setting of limb ischemia and may represent an alternative to VEGF-A for strategies of therapeutic angiogenic in patients with limb and/or myocardial ischemies.